Prostate cancer prevention by aspirin and/or other nsaids torfp 2016-E03HHSN2612015000381PERIOD of performance: 07/07/2016 - 03/06/2019
Ended Awarded Last action
- Contract number
- HHSN26100005
- Awardee
-
University Of Oklahoma UEI GY8NMUZQXVS7 Part of University Of Oklahoma
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $834,263
Award facts
- Opportunity
-
- N01CN5500347 Solicitation number
- Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers Award Notice · Posted Sep 25, 2015
- Preclinical PREVENT Cancer Program for Preclinical Efficacy and Intermediate Endpoint Biomarkers Award Notice · Posted Jan 5, 2015
- Contract value 100% obligated
- $834,263.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Oklahoma City, OK 73104, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$2,600 | |
| Supplemental Agreement for work within scope | $94,730 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $117,040 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $625,093 |
About this award
This is a delivery order issued under the National Cancer Institute's PREVENT Cancer Program (PREVENT) contract. The order, valued at $834,263.00, was awarded to the University of Oklahoma Health Sciences Center (OUHSC) to determine the potential clinical usefulness of aspirin and naproxen (another NSAID) for prostate cancer prevention using preclinical models. The University of Colorado-Denver is a subcontractor supporting this research. The award has a period of performance from July 2016 to March 2019, with a final completion date of July 2021. This contract is part of the NCI's Preclinical Prevention Cancer Program, which focuses on evaluating the efficacy and intermediate endpoint biomarkers of potential cancer prevention approaches. The contract does not have a set-aside designation.
Quick answers
Who was awarded contract HHSN26100005?
HHSN26100005 was awarded to University Of Oklahoma by National Cancer Institute (National Institutes of Health) on July 8, 2016.
How much is contract HHSN26100005 worth?
The government has obligated $834,263 on HHSN26100005.
Is contract HHSN26100005 an order under another contract?
Yes. HHSN26100005 is a delivery order under HHSN261201500038I, an indefinite delivery contract, on PREVENT Cancer Program (PREVENT).
Was contract HHSN26100005 competed?
The extent of competition for HHSN26100005 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award